AngstromInc.com
About AngstromInc.com
Ångstrom Pharmaceuticals, Inc. is a venture-backed pharmaceutical company. Ångstrom's proprietary products target a clearly-defined pathway, the Urokinase Plasminogen Activation System (PA), which has repeatedly been shown in scientific literature to be directly involved in proliferative diseases, such as cancer and wet age-related macular degeneration (ARMD). The Company's lead product, Å6, has completed a Phase 2 clinical trial for ovarian cancer.
